<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052205</url>
  </required_header>
  <id_info>
    <org_study_id>2125-RST-101</org_study_id>
    <nct_id>NCT03052205</nct_id>
  </id_info>
  <brief_title>A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors</brief_title>
  <acronym>ILLUMINATE-101</acronym>
  <official_title>A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idera Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate&#xD;
      promising clinical or biological activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">July 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Number of patients with treatment-related adverse events as assessed by CTCAE to determine the recommended Phase 2 dose (RP2D).</measure>
    <time_frame>51 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Objective response rate</measure>
    <time_frame>Assessed every 6 weeks for duration of study participation, which is estimated to be 51 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Melanoma Expansion Cohort: Objective response rate</measure>
    <time_frame>Assessed every 9 weeks for duration of study participation, which is estimated to be 51 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Melanoma Expansion Cohort: Number of patients with treatment-related adverse events as assessed by CTCAE</measure>
    <time_frame>51 weeks of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Refractory Solid Tumors</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>IMO-2125 at escalating dose levels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMO-2125 at escalating dose levels by intratumoral injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-2125</intervention_name>
    <description>IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.</description>
    <arm_group_label>IMO-2125 at escalating dose levels</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically or cytologically confirmed diagnosis of cancer not&#xD;
             amenable to curative therapy.&#xD;
&#xD;
          2. Patients who have a diagnosis for which a PD-(L)-1 inhibitor has been approved must&#xD;
             have previously received treatment with one of these therapies.&#xD;
&#xD;
             a. Melanoma Dose Expansion: Patients must have histologically confirmed metastatic&#xD;
             melanoma (ocular melanoma not included) which has progressed on or after treatment&#xD;
             with a PD-(L)1 inhibitor.&#xD;
&#xD;
          3. a) Dose Evaluation Portion: Patients should have at least one lesion accessible for&#xD;
             intratumoral injection and biopsy.&#xD;
&#xD;
             b) Melanoma Expansion Cohort: Patients must have at least one target lesion by&#xD;
             Response Evaluation Criteria for Solid Tumors (RECIST v1.1), with at least one lesion&#xD;
             accessible for intratumoral injection. Tumor biopsies are not required in the&#xD;
             expansion cohort.&#xD;
&#xD;
          4. Patients must be 18 years of age or older.&#xD;
&#xD;
          5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.&#xD;
&#xD;
          6. Patients must meet the following laboratory criteria:&#xD;
&#xD;
               1. Absolute neutrophil count ANC ≥1.5 x 109/L (≥1500/mm3)&#xD;
&#xD;
               2. Platelet count ≥75 x 109/L (≥75,000/mm3)&#xD;
&#xD;
               3. Hemoglobin ≥8.0 g/dL (≥4.96 mmol/L)&#xD;
&#xD;
               4. Serum creatinine ≤1.5 x ULN or calculated 24-hour creatinine clearance ≥60&#xD;
                  mL/minute&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) ≤2.5 x ULN; ALT ≤2.5 x ULN or AST/ALT &lt;5 x ULN&#xD;
                  if liver involvement&#xD;
&#xD;
               6. Total bilirubin ≤1.5 x ULN, except in patients with Gilbert's Syndrome who must&#xD;
                  have a total bilirubin &lt;3 mg/dL (51.3 μmol/L)&#xD;
&#xD;
          7. Women of childbearing potential and men must agree to use effective contraceptive&#xD;
             methods from Screening throughout the study treatment period and until at least 4&#xD;
             weeks after the last dose of study drug.&#xD;
&#xD;
          8. Patients must be willing and able to provide signed informed consent and comply with&#xD;
             the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received prior therapy with a TLR agonist Patients who have received&#xD;
             experimental vaccines or immune therapies other than PD-(L)1 or cytotoxic&#xD;
             T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (e.g., Imlygic®) should be&#xD;
             discussed with the Medical Monitor to confirm eligibility.&#xD;
&#xD;
             Note: (prior treatment with a topical TLR agonist (e.g. imiquimod) is permitted).&#xD;
&#xD;
          2. Patients who have received treatment with IFN-α within the previous 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          3. Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be&#xD;
             adequately managed with appropriate prophylaxis; e.g. steroids.&#xD;
&#xD;
          4. Patients with active autoimmune disease requiring disease-modifying therapy.&#xD;
&#xD;
          5. Patients requiring concurrent systemic steroid therapy higher than physiologic dosage&#xD;
             (&gt;10mg/day of prednisone or equivalent).&#xD;
&#xD;
          6. Patients with another primary malignancy that has not been in remission for at least 3&#xD;
             years, unless approved by the Idera Medical Monitor. The following are exempt from the&#xD;
             3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer&#xD;
             with non-detectable prostate-specific antigen, cervical carcinoma in situ on biopsy or&#xD;
             a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and thyroid cancer&#xD;
             (except anaplastic).&#xD;
&#xD;
          7. Patients with active infections requiring systemic treatment.&#xD;
&#xD;
          8. Patients who are known to be hepatitis B surface antigen positive.&#xD;
&#xD;
          9. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding.&#xD;
&#xD;
         11. Patients with known central nervous system, meningeal, or epidural disease. Patients&#xD;
             with stable brain metastases following definitive local treatment are eligible if&#xD;
             steroid requirement is &lt;10 mg/day of prednisone (or equivalent).&#xD;
&#xD;
         12. Patients with impaired cardiac function or clinically significant cardiac disease:&#xD;
&#xD;
               1. New York Heart Association Class III or IV cardiac disease, including preexisting&#xD;
                  clinically significant ventricular arrhythmia, congestive heart failure, or&#xD;
                  cardiomyopathy&#xD;
&#xD;
               2. Unstable angina pectoris ≤6 months prior to study participation&#xD;
&#xD;
               3. Acute myocardial infarction ≤6 months prior to study participation&#xD;
&#xD;
               4. Other clinically significant heart disease (i.e., Grade ≥3 hypertension, history&#xD;
                  of labile hypertension, or poor compliance with an anti-hypertensive regimen)&#xD;
&#xD;
         13. Have not recovered (to baseline or Grade ≤1) from toxicity associated with prior&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Idera Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Idera Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals DBA Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Beilinson Campus</name>
      <address>
        <city>Petah tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ella Lemelbaum Institute for Immuno-Oncology</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ILLUMINATE-101</keyword>
  <keyword>melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

